{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001372299","name":"Ocugen, Inc.","summary":"Ocugen, Inc. is a late-stage biotechnology company developing gene therapies for blindness and retinal diseases. Its novel modifier gene therapy platform includes OCU400 for retinitis pigmentosa, OCU410ST for Stargardt disease, and OCU410 for geographic atrophy secondary to dry AMD. The company also develops OCU200, a biologic for DME/DR/wet AMD, NeoCart for knee cartilage repair, and an inhaled mucosal vaccine platform including OCU500 (COVID-19) and influenza candidates.","people":[],"products":[{"name":"OCU400","type":"platform","description":"Modifier gene therapy using nuclear hormone receptors for retinitis pigmentosa; gene-agnostic approach for early to advanced cases."},{"name":"OCU410ST","type":"platform","description":"Modifier gene therapy delivering human RORA gene for Stargardt disease (ABCA4-associated retinopathies) via subretinal AAV5."},{"name":"OCU410","type":"platform","description":"Modifier gene therapy delivering human RORA gene for geographic atrophy secondary to dry AMD via subretinal AAV5."},{"name":"OCU200","type":"platform","description":"Novel recombinant fusion protein of tumstatin and transferrin for DME, diabetic retinopathy, and wet AMD."},{"name":"NeoCart","type":"platform","description":"Autologous chondrocyte-derived neocartilage regenerative cell therapy for repair of knee cartilage injuries in adults."},{"name":"OCU500","type":"platform","description":"Inhaled mucosal COVID-19 vaccine candidate with IND in effect; Phase 1 trial intended by NIAID."},{"name":"OCU510","type":"platform","description":"Inhaled mucosal seasonal quadrivalent influenza vaccine candidate."},{"name":"OCU520","type":"platform","description":"Inhaled mucosal combination quadrivalent seasonal flu and COVID-19 vaccine candidate."}],"partnerships":[{"partner_name":"National Institute of Allergy and Infectious Diseases (NIAID)","partnership_type":"development","description":"NIAID intends to initiate a Phase 1 clinical trial for OCU500 COVID-19 inhaled vaccine in Q2 2026.","start_date":null}],"affiliations":[],"origin":{"leaf":"60f7975712267f54062e02749662a880cd4ef0199f4d12c894d5027a160b541c","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"dddabd5ed11069d4522d9e49020239f6088887b39e08e6ab61f5e6dc997357bc","parent":"3abd30dfb95145f8026bf43c6e5bb0cca2eccffcf46c6e1cfe39a2732d7b946e","source":"0001628280-26-014435","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":104,"hourly_limit":500,"remaining":396,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}